←
Perspectum2,402 posts
Perspectum avatar

Perspectum

@PerspectumGroup

Perspectum® | Innovating medical imaging in Oxford - where tradition meets technology. AI-driven, patient-focused, advancing healthcare.

◷ Joined February 2014▧ 1,272 Photos and videos
Perspectum avatar
Perspectum@PerspectumGroup·13h

New publication from our digital pathology team: AI can map where inflammation sits in the liver, zone by zone, and the pattern differs between liver diseases. Liver biopsies are central to clinical trials for MASH, but scores can vary between pathologists. This work, published in the @bmj_latest , used AI to map inflammation in 553 biopsy slides from people with MASLD, MASH and AIH. The map runs from the portal tract, where blood enters the liver, to the central vein, where it drains out. What the results showed: The AI mapped all four liver zones in 553 of 572 slides (96.7%). Inflammation was highest at the edge of the portal tract and rose again near the central vein, most clearly in AIH with advanced fibrosis (scarring). Fat droplets were significantly larger in MASH than in MASLD (260 vs 190 μm²). Why it matters: objective, mapped measurements can complement pathologist scoring, adding detail on where disease activity sits in the liver. Led by Dylan Windell, Jack Breen and Tom Davis with the Perspectum digital pathology team and collaborators. Thank you to the full author team. Read the paper: doi.org/10.1136/jcp-2026-211… #Perspectum #MASH #DigitalPathology

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 17

BMI tells you about weight. It does not tell you where the fat sits. For endocrinologists, diabetologists and primary care teams, that is the question worth asking this Diabetes Awareness Month: where is the fat, and what is happening to muscle? In 75,331 UK Biobank participants, people with more visceral fat on MRI were almost twice as likely to develop type 2 diabetes, after adjusting for age, sex and BMI (HR 1.82, 95% CI 1.57 to 2.11, single slice at L3). Visceral fat was also associated with liver-related hospitalisation, major adverse cardiovascular events and chronic kidney disease. Perspectum Body Composition offers a non-invasive evaluation of body fat and muscle composition. From a non-contrast MRI at L3 in the abdomen, it reports visceral fat, subcutaneous fat and muscle area as quantified metrics, with composite images for visual differentiation of fat and muscle. Results are interpreted by trained healthcare professionals. Perspectum Body Composition is not intended to be used for any specific disease or condition, must not be used for direct diagnosis of patients, and its output must not be used on its own to make treatment decisions. Find out more: perspectum.com/clinical-solu… Endocrinologists and diabetologists: when you look at cardiometabolic risk today, what tells you where fat sits? Waist circumference, imaging, or nothing yet? #Perspectum #DiabetesAwarenessMonth #BodyComposition

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 16

Monitoring meaningful change in biliary disease can be complex. In a clinical trial, it has to be measurable. Strictures and dilatations are often the features a study needs to track. Objective, quantified metrics give trial teams consistent data to sit alongside visual review, supporting assessment and decision-making. MRCP+ is a quick, non-invasive, non-contrast MRI solution that provides quantitative assessment and 3D visualization of the biliary tree and pancreatic duct, from newly acquired or historic non-contrast MRCP images. It is used in research and clinical trials in biliary conditions such as primary sclerosing cholangitis (PSC). In a single examination, MRCP+ reports metrics at two levels. Whole biliary tree: Biliary tree volume (mL) Total number of ducts, strictures and dilatations (count) Percent of ducts with median width greater than 3 mm up to 5 mm (%) Individual ducts: Maximum common bile duct diameter (mm) Duct-level widths, strictures and dilatations (mm) Each metric is paired with 3D visualizations and reference ranges to aid interpretation. What is the hardest part of measuring biliary change in your studies today? Learn more about MRCP+: perspectum.com/products/mrcp… #Perspectum #TLM26 #ClinicalTrials

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 14

Liver fat can accumulate silently for years. For people living with type 2 diabetes, that matters. It is the reason Perspectum exists. We build quantitative imaging technology that gives clinicians a clearer view of the liver, without a needle or contrast agent. LiverMultiScan is a non-invasive, non-contrast liver health assessment. It provides quantified metrics for liver disease activity (cT1), liver fat (PDFF) and liver iron, to be interpreted by trained healthcare professionals. It facilitates early detection of changes to liver health, so the liver can be part of the conversation from the start. This World Diabetes Day, we are thinking of the people behind those numbers: patients, the clinicians caring for them, and the researchers working on what comes next. Clinicians: when someone with type 2 diabetes comes in for a review, how is liver health assessed in your setting today? #Perspectum #WorldDiabetesDay #LiverHealth

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 13

In 109 adults with type 2 diabetes, higher liver disease activity on MRI went hand in hand with greater insulin resistance. That is the finding of a study published this year in The Journal of Clinical Endocrinology and Metabolism by Ortiz Rocha and colleagues. The question the authors asked: in people with type 2 diabetes seen in primary care, does liver disease activity, measured by iron-corrected T1 (cT1) on a LiverMultiScan exam, track with wider cardiometabolic risk? What they found: higher cT1 was associated with more severe features of metabolic syndrome, higher insulin resistance (HOMA-IR) and greater adipose tissue dysfunction (all P < .01). Their conclusion: cT1 may help early identification of individuals at greater risk of liver disease progression and cardiometabolic disease. Tomorrow is World Diabetes Day, and the International Diabetes Federation’s theme for 2026 to 2027 is early action on diabetes. This study is a reminder that the liver is part of that picture, and that liver disease activity can be measured without a needle. For researchers in diabetes, hepatology and imaging: in your cohorts, where does liver disease activity sit alongside the metabolic measures you already collect? Ortiz Rocha, A. et al. (2026) ‘Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes’, The Journal of Clinical Endocrinology and Metabolism, 111(7), pp. e1813 to e1822. doi.org/10.1210/clinem/dgag0… #Perspectum #WorldDiabetesDay #Type2Diabetes

Post attachmentPost attachmentPost attachmentPost attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 12

We’re heading to @RSNA 2026 in Chicago, November 29 to December 3. Eleven members of the Perspectum team will be at #RSNA26, and you’ll find us at booth #5129, South Hall Level 3. For radiologists and imaging teams: see how LiverMultiScan supports non-invasive liver health assessment, with quantified metrics for liver disease activity (cT1), liver fat fraction (PDFF) and liver iron concentration to inform clinical decisions across diagnosis, treatment and monitoring. We’ll share more on what we’re presenting in the coming weeks. #Perspectum #RSNA26 #Radiology

Post attachmentPost attachmentPost attachmentPost attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 12

In 89 boys aged 6 to 11, cT1 correlated with inflammatory cytokines; its link with IL-10 held after adjusting for BMI and liver fat. Luis Felipe Cardiel presents at ObesityWeek 2026, Sat Nov 14, 3:00 pm ET. #Perspectum #MASLD

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 11

Preclinical obesity plus MRI-detected organ abnormalities: hazard ratio 13 (95% CI 7.0 to 25) for new-onset type 2 diabetes in 32,129 UK Biobank adults. ObesityWeek 2026 poster, Mon Nov 16, 2:30 pm ET, Exhibit Hall BCD. #Perspectum

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 11

A roughly 10-minute abdominal MRI estimated resting energy expenditure with a coefficient of variation of 1.11% between repeat scans and 1.03% across three scanners. ObesityWeek 2026 poster, Sat Nov 14, 7:30 pm ET, Exhibit Hall BCD. #Perspectum

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 10

Two people can lose the same amount of weight and end up in very different physiological states. One loses visceral fat. The other loses muscle. Body weight alone cannot tell them apart. That gap is where our conversations at ObesityWeek 2026 will start. We will be at The Obesity Society’s 44th Annual Meeting, 14 to 17 November at the Gaylord National Resort and Convention Center, National Harbor, MD. #Perspectum #ObesityWeek2026 #BodyComposition

Post attachmentPost attachmentPost attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 9

Whole-tree volume. Duct counts. Strictures. Dilatations. Quantified from one non-contrast MRCP scan. MRCP+ reports metrics for the whole biliary tree and for individual ducts. Here is what each describes: Whole biliary tree: Biliary tree volume (mL): the volume of the modeled biliary tree. Total ducts, strictures and dilatations (count): the number of narrowed and widened duct segments, and the number of ducts with either. Percent of ducts with median width greater than 3 mm up to 5 mm (%): how much of the tree sits in that width range. Individual ducts: Duct-level widths, strictures and dilatations (mm): the median, minimum, maximum and interquartile widths, as well as locations of narrowed and widened segments, of select ducts Each report pairs these metrics with 3D visualizations and reference ranges to aid interpretation, giving specialists and referring clinicians objective data to complement visual interpretation. MRCP is used in biliary conditions such as primary sclerosing cholangitis (PSC). Which of these measurements would be most useful in your practice? #Perspectum #TLM26 #Hepatology

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 8

Day 2 of @AASLDtweets The Liver Meeting in Denver. Find Perspectum at booth #1055 until 5:00 PM MT today. This week our work was shared in five posters and one oral presentation, covering digital pathology and biopsy reading, liver disease screening, cirrhosis risk, liver and heart health in people with high blood pressure, and autoimmune liver disease in children. If you’re at the meeting, come and say hello before we pack up. To book time with us about clinical trials, email Pharma.Business.Development@perspectum.com. #Perspectum #TLM26 #Hepatology #LiverDisease

Post attachmentPost attachmentPost attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 6

Day two at @AASLDtweets The Liver Meeting, and we have three posters for you to stop by in one hour. Find us at booth #1055 in Denver. Today’s Poster Session II runs from 1:00 to 2:00 PM MT. Poster #2329: cT1 as the second step in the MASLD screening pathway, after a FIB-4 blood test. Led by Niharika Samala, Associate Professor of Medicine, Indiana University Poster #2422: an MRI risk model for identifying cirrhosis in people with MASLD. Led by Charlie Diamond, Biomarker Scientist, Perspectum, with the ELEGANCE Consortium. Poster #2443: MRI of the liver and heart together in adults with high blood pressure, with and without type 2 diabetes. Led by Yameng Deng, Scientist II, Perspectum with the REMODEL study team. All three use cT1, an MRI measure of liver disease activity. We’ll share what each one found in its own post today. The team is at booth #1055 through Sunday, November 8. To book time with us, email Pharma.Business.Development@perspectum.com. #Perspectum #TLM26 #Hepatology #LiverDisease

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 5

Day one at @AASLDtweets The Liver Meeting. Find Perspectum at booth #1055 in Denver. Our team is here through Sunday, November 8, and we’d like to meet you. Stop by to talk liver imaging in clinical practice, or quantitative liver imaging biomarkers in liver disease trials! Where to find our science this week: Today, Thursday, November 5, 12:00 to 1:00 PM MT, Poster Hall, Hall DE Poster #1439: digitized whole slide imaging for METAVIR fibrosis staging Poster #1436: consensus biopsy reading in a Phase III AATD program Friday, November 6, 1:00 to 2:00 PM MT, Poster Session II Poster #2329: cT1 as the second step in the MASLD screening pathway Poster #2422: a multiparametric MRI risk model for identifying cirrhosis Poster #2443: multi-organ MRI of the liver and heart in adults with hypertension Saturday, November 7, 11:00 AM to 12:30 PM MT Oral presentation in Precision Hepatology in Children: Novel Therapies, Biomarkers, and Clinical Outcomes, on imaging and plasma biomarkers in pediatric autoimmune liver disease Want time with the team? Come to the booth, or email Pharma.Business.Development@perspectum.com if you would like a conversation on clinical trials. #Perspectum #TLM26 #Hepatology

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 4

Three questions clinical trial teams ask us about quantitative MRCP, answered before The Liver Meeting. Can we use the MRCP our sites already acquire? Yes. MRCP+ can analyze newly acquired or historic non-contrast MRCP images, on a cloud-based platform with no additional hardware or software required. How much of the biliary tree is quantified? Quantitative assessment of biliary system structures across the intra and extra-hepatic biliary tree: bile duct widths, strictures and dilatations, plus the pancreatic ducts, gallbladder and regional volumetric analysis. How does it sit alongside the radiologist’s read? Quantified metrics, enhanced 3D visualizations and reference ranges to aid interpretation, designed to sit alongside visual review. Our team is in Denver at AASLD The Liver Meeting from November 5 to 9. Book time with us at booth #1055. Find out more: perspectum.com/products/mrcp… #Perspectum #TLM26 #ClinicalTrials

Post attachment
Perspectum avatar
Perspectum@PerspectumGroup·Nov 4

Two posters at #ScientificSessions26: epicardial fat in type 2 diabetes (MDP0137, Sat, Nov 7, 9:15 AM CT) and coexisting heart and liver abnormalities in hypertension (REMODEL, MDP1904, Sun, Nov 8, 3:15 PM CT). Abstract data, not yet peer reviewed. #Perspectum

Post attachmentPost attachment